361 related articles for article (PubMed ID: 9199708)
1. Monoclonal antibodies to the distinct antigenic sites on glycoproteins C and B and their protective abilities in herpes simplex virus infection.
Bystrická M; Petríková M; Zatovicová M; Soláriková L; Kostolanský F; Mucha V; Russ G
Acta Virol; 1997 Feb; 41(1):5-12. PubMed ID: 9199708
[TBL] [Abstract][Full Text] [Related]
2. Human natural killer cell recognition of herpes simplex virus type 1 glycoproteins: specificity analysis with the use of monoclonal antibodies and antigenic variants.
Bishop GA; Marlin SD; Schwartz SA; Glorioso JC
J Immunol; 1984 Oct; 133(4):2206-14. PubMed ID: 6206157
[TBL] [Abstract][Full Text] [Related]
3. Protection of nude mice by passive immunization with a type-common human recombinant monoclonal antibody against HSV.
Sanna PP; De Logu A; Williamson RA; Hom YL; Straus SE; Bloom FE; Burton DR
Virology; 1996 Jan; 215(1):101-6. PubMed ID: 8553581
[TBL] [Abstract][Full Text] [Related]
4. Identification of herpes simplex virus type 1 (HSV-1) glycoprotein gC as the immunodominant antigen for HSV-1-specific memory cytotoxic T lymphocytes.
Glorioso J; Kees U; Kümel G; Kirchner H; Krammer PH
J Immunol; 1985 Jul; 135(1):575-82. PubMed ID: 2582051
[TBL] [Abstract][Full Text] [Related]
5. Identification of B- and T-cell epitopes from glycoprotein B of herpes simplex virus 2 and evaluation of their immunogenicity and protection efficacy.
Liu K; Jiang D; Zhang L; Yao Z; Chen Z; Yu S; Wang X
Vaccine; 2012 Apr; 30(19):3034-41. PubMed ID: 22008818
[TBL] [Abstract][Full Text] [Related]
6. Genetic immunization against herpes simplex virus. Protection is mediated by CD4+ T lymphocytes.
Manickan E; Rouse RJ; Yu Z; Wire WS; Rouse BT
J Immunol; 1995 Jul; 155(1):259-65. PubMed ID: 7602102
[TBL] [Abstract][Full Text] [Related]
7. Purification of herpes simplex virus glycoproteins B and C using monoclonal antibodies and their ability to protect mice against lethal challenge.
Roberts PL; Duncan BE; Raybould TJ; Watson DH
J Gen Virol; 1985 May; 66 ( Pt 5)():1073-85. PubMed ID: 2582080
[TBL] [Abstract][Full Text] [Related]
8. Herpes simplex virus type 1 envelope subunit vaccine not only protects against lethal virus challenge, but also may restrict latency and virus reactivation.
Rajcáni J; Sabó A; Mucha V; Kostál M; Compel P
Acta Virol; 1995 Feb; 39(1):37-49. PubMed ID: 7572468
[TBL] [Abstract][Full Text] [Related]
9. Prevention of herpes keratitis by monoclonal antibodies specific for discontinuous and continuous epitopes on glycoprotein D.
Lousch RN; Staats H; Oakes JE; Cohen GH; Eisenberg RJ
Invest Ophthalmol Vis Sci; 1991 Sep; 32(10):2735-40. PubMed ID: 1716618
[TBL] [Abstract][Full Text] [Related]
10. Structure-function analysis of herpes simplex virus glycoprotein B with fusion-from-without activity.
Roller DG; Dollery SJ; Doyle JL; Nicola AV
Virology; 2008 Dec; 382(2):207-16. PubMed ID: 18950828
[TBL] [Abstract][Full Text] [Related]
11. Passive immune protection by herpes simplex virus-specific monoclonal antibodies with different plaque development inhibition activity.
Mannini-Palenzona A; Costanzo F; Cassai E; Campana G
New Microbiol; 1993 Jul; 16(3):205-13. PubMed ID: 8396193
[TBL] [Abstract][Full Text] [Related]
12. A novel glycoprotein D-specific monoclonal antibody neutralizes herpes simplex virus.
Du R; Wang L; Xu H; Wang Z; Zhang T; Wang M; Ning Y; Deng F; Hu Z; Wang H; Li Y
Antiviral Res; 2017 Nov; 147():131-141. PubMed ID: 29061442
[TBL] [Abstract][Full Text] [Related]
13. Variability of herpes simplex virus 1 gL and anti-gL antibodies that inhibit cell fusion but not viral infectivity.
Novotny MJ; Parish ML; Spear PG
Virology; 1996 Jul; 221(1):1-13. PubMed ID: 8661409
[TBL] [Abstract][Full Text] [Related]
14. Passive immune protection by herpes simplex virus-specific monoclonal antibodies and monoclonal antibody-resistant mutants altered in pathogenicity.
Kümel G; Kaerner HC; Levine M; Schröder CH; Glorioso JC
J Virol; 1985 Dec; 56(3):930-7. PubMed ID: 2415719
[TBL] [Abstract][Full Text] [Related]
15. Type-common and type-specific monoclonal antibodies to herpes simplex virus types 1 and 2.
Bystrická M; Vancíková M; Kasalová M; Rajcáni J; Kostál M; Murányiová M; Poláková K; Russ G
Acta Virol; 1991 Apr; 35(2):152-64. PubMed ID: 1681713
[TBL] [Abstract][Full Text] [Related]
16. Intravascular naked DNA vaccine encoding glycoprotein B induces protective humoral and cellular immunity against herpes simplex virus type 1 infection in mice.
Cui FD; Asada H; Kishida T; Itokawa Y; Nakaya T; Ueda Y; Yamagishi H; Gojo S; Kita M; Imanishi J; Mazda O
Gene Ther; 2003 Dec; 10(25):2059-66. PubMed ID: 14595378
[TBL] [Abstract][Full Text] [Related]
17. Glycoprotein C of Herpes Simplex Virus 1 Shields Glycoprotein B from Antibody Neutralization.
Komala Sari T; Gianopulos KA; Nicola AV
J Virol; 2020 Feb; 94(5):. PubMed ID: 31826995
[TBL] [Abstract][Full Text] [Related]
18. Comparison of different forms of herpes simplex replication-defective mutant viruses as vaccines in a mouse model of HSV-2 genital infection.
Da Costa XJ; Morrison LA; Knipe DM
Virology; 2001 Sep; 288(2):256-63. PubMed ID: 11601897
[TBL] [Abstract][Full Text] [Related]
19. Characterization of B virus glycoprotein antibodies induced by DNA immunization.
Perelygina L; Patrusheva I; Zurkuhlen H; Hilliard JK
Arch Virol; 2002 Nov; 147(11):2057-73. PubMed ID: 12417944
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-12- and gamma interferon-dependent innate immunity are essential and sufficient for long-term survival of passively immunized mice infected with herpes simplex virus type 1.
Vollstedt S; Franchini M; Alber G; Ackermann M; Suter M
J Virol; 2001 Oct; 75(20):9596-600. PubMed ID: 11559791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
